<DOC>
	<DOCNO>NCT00514371</DOCNO>
	<brief_summary>This phase 2/3 , open label trial patient relapsed-refractory multiple myeloma . Study agent tanespimycin ( KOS-953 ) , three different dose level combination fix dose bortezomib .</brief_summary>
	<brief_title>A Study Tanespimycin ( KOS-953 ) Patients With Relapsed-refractory Multiple Myeloma</brief_title>
	<detailed_description>Phase 2/3 combination study compare bortezomib plus one three dos tanespimycin patient relapsed-refractory multiple myeloma failure least three prior anti-cancer therapy regimen . Prior therapy must include bortezomib lenalidomide . Primary objective ass dose-response relationship objective response rate ( ORR ) use EBMT/IBMTR criterion three dose level tanespimycin ( KOS-953 ) combination bortezomib four treatment cycle .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Good performance status Histologic evidence multiple myeloma Have least three prior treatment regimens multiple myeloma include bortezomib lenalidomide No prior treatment heat shock 90 inhibitor investigational proteasome inhibitor No known infection HAV , HBV , HCV , HIV No chemotherapy , radiation therapy , immune therapy three week prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Heat Shock Protein 90</keyword>
	<keyword>Hsp90</keyword>
	<keyword>KOS-953</keyword>
	<keyword>17-AAG</keyword>
	<keyword>bortezomib</keyword>
	<keyword>relapsed-refractory</keyword>
	<keyword>tanespimycin</keyword>
</DOC>